4.7 Article

Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink Project

期刊

PEDIATRICS
卷 127, 期 -, 页码 S54-S64

出版社

AMER ACAD PEDIATRICS
DOI: 10.1542/peds.2010-1722I

关键词

vaccines; surveillance; epidemiologic methods; statistics

资金

  1. Merck
  2. Wyeth (now Pfizer)
  3. Novartis
  4. Sanofi Pasteur
  5. GlaxoSmithKline
  6. MedImmune (now AstraZeneca)
  7. Centers for Disease Control and Prevention [200-2002-00732]

向作者/读者索取更多资源

OBJECTIVE: To describe the Vaccine Safety Datalink (VSD) project's experience with population-based, active surveillance for vaccine safety and draw lessons that may be useful for similar efforts. PATIENTS AND METHODS: The VSD comprises a population of 9.2 million people annually in 8 geographically diverse US health care organizations. Data on vaccinations and diagnoses are updated and extracted weekly. The safety of 5 vaccines was monitored, each with 5 to 7 prespecified outcomes. With sequential analytic methods, the number of cases of each outcome was compared with the number of cases observed in a comparison group or the number expected on the basis of background rates. If the test statistic exceeded a threshold, it was a signal of a possible vaccine-safety problem. Signals were investigated by using temporal scan statistics and analyses such as logistic regression. RESULTS: Ten signals appeared over 3 years of surveillance: 1 signal was reported to external stakeholders and ultimately led to a change in national vaccination policy, and 9 signals were found to be spurious after rigorous internal investigation. Causes of spurious signals included imprecision in estimated background rates, changes in true incidence or coding over time, other confounding, inappropriate comparison groups, miscoding of outcomes in electronic medical records, and chance. In the absence of signals, estimates of adverse-event rates, relative risks, and attributable risks from up-to-date VSD data have provided rapid assessment of vaccine safety to policy-makers when concerns about a specific vaccine have arisen elsewhere. CONCLUSIONS: Care with data quality, outcome definitions, comparison groups, and length of surveillance are required to enable detection of true safety problems while minimizing false signals. Some causes of false signals in the VSD system were preventable and have been corrected, whereas others will be unavoidable in any active surveillance system. Temporal scan statistics, analyses to control for confounding, and chart review are indispensable tools in signal investigation. The VSD's experience may inform new systems for active safety surveillance. Pediatrics 2011;127:S54-S64

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Mathematical & Computational Biology

Exact sequential analysis for multiple weighted binomial end points

Ivair R. Silva, Joshua J. Gagne, Mehdi Najafzadeh, Martin Kulldorff

STATISTICS IN MEDICINE (2020)

Article Infectious Diseases

Prediction of serious RSV-related outcomes in older adults with outpatient RSV respiratory illness during 12 consecutive seasons

Burney A. Kieke, Edward A. Belongia, David L. McClure, Vivek Shinde

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2020)

Article Immunology

Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination

Elizabeth Liles, Stephanie A. Irving, Padma Dandamudi, Edward A. Belongia, Matthew F. Daley, Frank DeStefano, Lisa A. Jackson, Steven J. Jacobsen, Elyse Kharbanda, Nicola P. Klein, Eric Weintraub, Allison L. Naleway

Summary: Recent studies have shown an increase in the incidence of inflammatory bowel disease (IBD) in young children over a ten-year period, but the data suggest that the rotavirus vaccination is not associated with the development of IBD.

VACCINE (2021)

Article Public, Environmental & Occupational Health

Trimethoprim-sulfamethoxazole resistance patterns among Staphylococcus aureus in the United States, 2012-2018

D. Cal Ham, Lucy Fike, Hannah Wolford, Lindsey Lastinger, Minn Soe, James Baggs, Maroya Spalding Walters

Summary: This study reviewed antibiotic susceptibility testing data of Staphylococcus aureus to trimethoprim-sulfamethoxazole in three national inpatient databases. The results showed an increasing percentage of methicillin-resistant Staphylococcus aureus that were not susceptible to trimethoprim-sulfamethoxazole. It is recommended that healthcare providers choose antibiotic regimens based on local resistance patterns and promptly report any changes to the public health department.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2023)

Article Infectious Diseases

mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021

Huong Q. McLean, David L. McClure, Jennifer P. King, Jennifer K. Meece, David Pattinson, Gabriele Neumann, Yoshihiro Kawaoka, Melissa A. Rolfes, Edward A. Belongia

Summary: The study found that the effectiveness of COVID-19 vaccines has decreased with the increasing prevalence of the SARS-CoV-2 Delta variant. Overall, two doses of mRNA COVID-19 vaccines showed an effectiveness of 56% against laboratory-confirmed SARS-CoV-2 infection, with Moderna vaccine at 65% and Pfizer-BioNTech vaccine at 50%. When the Delta variant was predominant, the effectiveness of mRNA COVID-19 vaccines was 54%, Moderna vaccine was 59%, and Pfizer-BioNTech vaccine was 52%.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2022)

Article Infectious Diseases

Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults

Sarah Spencer, Jessie R. Chung, Edward A. Belongia, Maria Sundaram, Jennifer Meece, Laura A. Coleman, Richard K. Zimmerman, Mary Patricia Nowalk, Krissy Moehling Geffel, Ted Ross, Chalise E. Carter, David Shay, Min Levine, Justine Liepkalns, Jin Hyang Kim, Suryaprakash Sambhara, Mark G. Thompson, Brendan Flannery

Summary: Individuals with type 2 diabetes mellitus and those without showed similar serologic responses to the trivalent influenza vaccine, with greater fold-increases in antibody titer occurring among those with lower pre-vaccination antibody titers. The waning of antibody titers was not influenced by diabetes status.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2022)

Article Immunology

Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years

Huong Q. McLean, Min Z. Levine, Jennifer P. King, Brendan Flannery, Edward A. Belongia

Summary: Sequential vaccination with enhanced vaccines did not reduce immunogenicity in adults aged 65 through 74 years. Serologic response to cell-propagated A/H3N2 was suboptimal for all vaccines.

VACCINE (2021)

Article Public, Environmental & Occupational Health

Trends in facility-level rates of Clostridioides difficile infections in US hospitals, 2019-2020

Ashley N. Rose, James Baggs, Sophia Kazakova, Alice Y. Guh, Sarah H. Yi, Natalie L. McCarthy, John A. Jernigan, Sujan C. Reddy

Summary: Despite significant changes to healthcare delivery and antibiotic prescribing during the COVID-19 pandemic, there was no significant change in Clostridioides difficile infection (CDI) trends. CDI rates showed a slight downward trajectory before the pandemic declaration, but this trend did not continue during the pandemic.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2023)

Article Infectious Diseases

Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022

Sara S. Kim, Jessie R. Chung, H. Keipp Talbot, Carlos G. Grijalva, Karen J. Wernli, Erika Kiniry, Emily T. Martin, Arnold S. Monto, Edward A. Belongia, Huong Q. McLean, Manjusha Gaglani, Mufaddal Mamawala, Mary Patricia Nowalk, Krissy Moehling Geffel, Sara Y. Tartof, Ana Florea, Justin S. Lee, Mark W. Tenforde, Manish M. Patel, Brendan Flannery

Summary: This study estimated the effectiveness of two and three doses of mRNA COVID-19 vaccines against symptomatic illness caused by the Delta and Omicron variants in US outpatient settings. The results showed that three doses of mRNA vaccines provided substantial protection against symptomatic illness when the Omicron variant became the predominant cause of COVID-19 in the United States. These findings support the recommendation for a third dose of mRNA COVID-19 vaccine.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2022)

Article Public, Environmental & Occupational Health

Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) outbreaks in nursing homes involving residents who had completed a primary coronavirus disease 2019 (COVID-19) vaccine series-13 US jurisdictions, July-November 2021

W. Wyatt Wilson, Amelia A. Keaton, Lucas G. Ochoa, Kelly M. Hatfield, Paige Gable, Kelly A. Walblay, Richard A. Teran, Meghan Shea, Urooj Khan, Ginger Stringer, Joanne G. Colletti, Erin M. Grogan, Carly Calabrese, Andrew Hennenfent, Rebecca Perlmutter, Katherine A. Janiszewski, Ishrat Kamal-Ahmed, Kyle Strand, Emily Berns, Jennifer MacFarquhar, Meghan Linder, Dat J. Tran, Patricia Kopp, Rebecca M. Walker, Rebekah Ess, Jennifer S. Read, Chelsey Yingst, James Baggs, John A. Jernigan, Alex Kallen, Jennifer C. Hunter

Summary: Among nursing home outbreaks of COVID-19 with the SARS-CoV-2 Delta variant as the predominant circulating strain, fully vaccinated residents had a 28% lower risk of infection compared to unvaccinated residents. Once infected, vaccinated residents had approximately half the risk of hospitalization and death from any cause compared to unvaccinated infected residents.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2023)

Article Immunology

Burden of medically attended influenza infection and cases averted by vaccination-United States, 2016/17 through 2018/19 influenza seasons

Michael L. Jackson, C. Hallie Phillips, Stacie Wellwood, Erika Kiniry, Lisa A. Jackson, Emily T. Martin, Arnold S. Monto, Huong Q. McLean, Edward A. Belongia, Manjusha Gaglani, Kayan Dunnigan, Chandni Raiyani, Kempapura Murthy, Brendan Flannery, Jessie R. Chung

Summary: This study estimated the number of influenza cases averted by vaccination in four ambulatory care sites in the United States, and it found that influenza vaccines can still reduce ambulatory care visits for influenza even in seasons with low vaccine effectiveness.

VACCINE (2022)

Article Infectious Diseases

Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network

Sara Y. Tartof, Fagen Xie, Ruchi J. Yadav, Karen J. T. Wernli, Emily T. A. Martin, Edward A. Belongia, Manjusha K. Gaglani, Richard K. Zimmerman, H. Keipp Talbot, Natalie Thornburg, Brendan Flannery, US Flu VE Network Investigators

Summary: This study assessed the combined protection conferred by prior SARS-CoV-2 infection and COVID-19 vaccination against COVID-19-associated acute respiratory illness. The results showed that among previously uninfected patients, three doses of mRNA COVID-19 vaccine had an effectiveness of 97% against the Delta variant, but the effectiveness against the Omicron variant was not statistically significant. Among previously infected patients, the three-dose vaccine had a protection rate of 57% against the Omicron variant, and the effectiveness against the Delta variant could not be estimated.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2023)

Article Infectious Diseases

Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022

Joshua G. Petrie, Jennifer P. King, David L. McClure, Melissa A. Rolfes, Jennifer K. Meece, David Pattinson, Gabriele Neumann, Yoshihiro Kawaoka, Edward A. Belongia, Huong Q. McLean

Summary: During the circulation of the Omicron variant virus, a monovalent COVID-19 mRNA booster vaccine showed significant protection against SARS-CoV-2 infection, but the effectiveness decreased over time. A second booster did not provide significant protection for adults aged 50 and above. Encouraging the uptake of recommended bivalent boosters is advised to enhance protection against the Omicron BA.4/BA.5 sublineages.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2023)

Article Immunology

Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022

Emily Jane Woo, Julianne Gee, Paige Marquez, James Baggs, Winston E. Abara, Michael M. McNeil, Rositsa B. Dimova, John R. Su

Summary: FDA authorized Janssen COVID-19 Vaccine for use in individuals 18 years and older. Vaccine safety was monitored using VAERS and v-safe. Most adverse events were non-serious, but a potential safety concern for myocarditis was identified.

VACCINE (2023)

Article Immunology

Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons

Stephanie A. Irving, Holly C. Groom, Edward A. Belongia, Bradley Crane, Matthew F. Daley, Kristin Goddard, Lisa A. Jackson, Tia L. Kauffman, Tat'Yana A. Kenigsberg, Leslie Kuckler, Allison L. Naleway, Suchita A. Patel, Hung Fu Tseng, Josh T. B. Williams, Eric S. Weintraub

Summary: In the United States, influenza vaccination coverage increased from 2017-18 to 2019-20, then decreased to the lowest level in the 2022-23 season. The lowest coverage was observed among males, individuals aged 18-49, non-Hispanic Black people, and those without high-risk conditions.

VACCINE (2023)

暂无数据